Aakash Desai, Assistant Professor and Associate Director of Phase 1 and Precision Oncology Program at the UAB O’Neal Comprehensive Cancer Center, shared a post on LinkedIn:
“Osimertinib + Dato-DXd post-osimertinib progression? ORCHARD says yes.
For 06 mg/kg dose:
- ORR: 36%
- mPFS: 11.7 mo
- mOS: 26.2 mo
- But caveat: 76% Grade 3+ AEs, 15% ILD/pneumonitis.”
Other articles about ORCHARD on OncoDaily.